S

South Texas Accelerated Research Therapeutics | START Madrid - CIOCC

Research site

(Unclaimed)

Location

Calle Oña 10,  Planta 3 Hospital Universitario HM Sanchinarro, Madrid, Madrid, Spain

Site insights

Top conditions

Top treatments

BOS172738

ATV-1601

EP102

Futibatinib

Temozolomide

KQB198

Fulvestrant

Tinostamustine

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced...

Enrolling

Ovarian Neoplasms

Ovarian Carcinoma

Drug: ATV-1601

Combination Product: ATV-1601 + Fulvestrant

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with tem...

Enrolling

Astrocytoma, Grade III

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Drug: Debio 0123

Drug: Temozolomide

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQ...

Enrolling

Solid Tumor, Adult

Drug: KQB198

Drug: osimertinib

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), t...

Enrolling

Advanced Solid Tumor (Phase 1)

Drug: EP102

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

The study is designed as an open label, multi-center, Phase 1 study of single agent tinostamustine, used as adjuvant treatment in patients with newly...

Active, not recruiting

Glioblastoma Multiforme

Drug: Tinostamustine